S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
Log in
NYSE:CRL

Charles River Laboratories International Stock Forecast, Price & News

$287.46
-2.15 (-0.74 %)
(As of 03/2/2021 04:31 PM ET)
Add
Compare
Today's Range
$286.81
Now: $287.46
$291.45
50-Day Range
$252.87
MA: $278.07
$299.48
52-Week Range
$95.58
Now: $287.46
$303.79
Volume215,604 shs
Average Volume336,080 shs
Market Capitalization$14.31 billion
P/E Ratio47.91
Dividend YieldN/A
Beta1.12
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Charles River Laboratories International logo

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP15986410
Phone781-222-6000
Employees18,400
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.62 billion
Cash Flow$11.42 per share
Book Value$33.45 per share

Profitability

Net Income$252.02 million

Miscellaneous

Market Cap$14.31 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.54 out of 5 stars

Medical Sector

396th out of 1,968 stocks

Commercial Physical Research Industry

9th out of 42 stocks

Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$287.46
-2.15 (-0.74 %)
(As of 03/2/2021 04:31 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Charles River Laboratories International (NYSE:CRL) Frequently Asked Questions

Is Charles River Laboratories International a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Charles River Laboratories International stock.
View analyst ratings for Charles River Laboratories International
or view top-rated stocks.

What stocks does MarketBeat like better than Charles River Laboratories International?

Wall Street analysts have given Charles River Laboratories International a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Charles River Laboratories International wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Charles River Laboratories International's next earnings date?

Charles River Laboratories International is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Charles River Laboratories International
.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) issued its quarterly earnings data on Tuesday, February, 16th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.11 by $0.28. Charles River Laboratories International had a trailing twelve-month return on equity of 22.41% and a net margin of 10.68%.
View Charles River Laboratories International's earnings history
.

How has Charles River Laboratories International's stock price been impacted by COVID-19?

Charles River Laboratories International's stock was trading at $136.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CRL shares have increased by 110.4% and is now trading at $287.46.
View which stocks have been most impacted by COVID-19
.

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International updated its FY 2021 Pre-Market earnings guidance on Wednesday, February, 17th. The company provided earnings per share (EPS) guidance of 9.00-9.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.86. The company issued revenue guidance of $3.275-3.333 billion, compared to the consensus revenue estimate of $3.19 billion.

What price target have analysts set for CRL?

16 Wall Street analysts have issued 1-year price targets for Charles River Laboratories International's stock. Their forecasts range from $145.00 to $350.00. On average, they anticipate Charles River Laboratories International's share price to reach $241.56 in the next year. This suggests that the stock has a possible downside of 16.0%.
View analysts' price targets for Charles River Laboratories International
or view top-rated stocks among Wall Street analysts.

Who are Charles River Laboratories International's key executives?

Charles River Laboratories International's management team includes the following people:
  • Mr. James C. Foster, Chairman, CEO & Pres (Age 70, Pay $5.38M)
  • Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 55, Pay $1.25M)
  • Mr. Joseph W. LaPlume, Corp. Exec. VP of Corp. Devel. & Strategy (Age 47, Pay $931.56k)
  • Ms. Birgit Girshick, Corp. EVP of Global Discovery & Safety Assessment, Biologics Testing Solutions & Avian Vaccine (Age 51, Pay $937.58k)
  • Mr. Michael Gunnar Knell, Corp. Sr. VP & Chief Accounting Officer (Age 44)
  • Mr. Arthur C. Hubbs, Corp. Sr. VP & Chief Information Officer
  • Todd Spencer, Corp. VP of Investor Relations
  • Mr. Matthew L. Daniel, Corp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
  • Ms. Amy Cianciaruso, Corp. VP of PR & Corp. Communications
  • Ms. Gina M. Mullane, Chief Marketing Officer & Corp. Sr. VP

What is James C. Foster's approval rating as Charles River Laboratories International's CEO?

291 employees have rated Charles River Laboratories International CEO James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among Charles River Laboratories International's employees.

Who are some of Charles River Laboratories International's key competitors?

What other stocks do shareholders of Charles River Laboratories International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), The Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), salesforce.com (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is Charles River Laboratories International's stock symbol?

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Who are Charles River Laboratories International's major shareholders?

Charles River Laboratories International's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.79%), Brown Advisory Inc. (1.72%), FIL Ltd (1.63%), Congress Asset Management Co. MA (1.20%), Victory Capital Management Inc. (1.12%) and Bank of New York Mellon Corp (1.10%). Company insiders that own Charles River Laboratories International stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Richard F Wallman, Robert J Bertolini, Stephen D Chubb and William D Barbo.
View institutional ownership trends for Charles River Laboratories International
.

Which institutional investors are selling Charles River Laboratories International stock?

CRL stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Renaissance Technologies LLC, Epoch Investment Partners Inc., Sculptor Capital LP, Hood River Capital Management LLC, First Trust Advisors LP, Victory Capital Management Inc., and Ariel Investments LLC. Company insiders that have sold Charles River Laboratories International company stock in the last year include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Robert J Bertolini, Stephen D Chubb, and William D Barbo.
View insider buying and selling activity for Charles River Laboratories International
or view top insider-selling stocks.

Which institutional investors are buying Charles River Laboratories International stock?

CRL stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Morgan Stanley, Clearbridge Investments LLC, FIL Ltd, Mackenzie Financial Corp, Nuveen Asset Management LLC, King Luther Capital Management Corp, and Squarepoint Ops LLC.
View insider buying and selling activity for Charles River Laboratories International
or or view top insider-buying stocks.

How do I buy shares of Charles River Laboratories International?

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Charles River Laboratories International's stock price today?

One share of CRL stock can currently be purchased for approximately $287.46.

How much money does Charles River Laboratories International make?

Charles River Laboratories International has a market capitalization of $14.31 billion and generates $2.62 billion in revenue each year. The medical research company earns $252.02 million in net income (profit) each year or $6.73 on an earnings per share basis.

How many employees does Charles River Laboratories International have?

Charles River Laboratories International employs 18,400 workers across the globe.

What is Charles River Laboratories International's official website?

The official website for Charles River Laboratories International is www.criver.com.

Where are Charles River Laboratories International's headquarters?

Charles River Laboratories International is headquartered at 251 BALLARDVALE STREET, WILMINGTON MA, 01887.

How can I contact Charles River Laboratories International?

Charles River Laboratories International's mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.